Larvol Delta - Celldex-Presents-Positive-Data-from-Phase-2-Chronic-Spontaneous-UrticariaStudies-Demonstrating-Rapid-Profound-and-Durable-Improvements-in-Patient-Quality-of-Life-at-AAD-2026

barzolvolimab (CDX-0159) - Celldex

https://www.globenewswire.com/news-release/2026/03/27/3263841/24180/en/Celldex-Presents-Positive-Data-from-Phase-2-Chronic-Spontaneous-Urticaria-and-Phase-2-Cold-Urticaria-and-Symptomatic-Dermographism-Studies-Demonstrating-Rapid-Profound-and-Durable-.html

Mar 27, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next